Fatal multi-organ failure after suicidal overdose with MDMA, 'Ecstasy': Case report and review of the literature

Human and Experimental Toxicology

Volumn 18, Issue 2, 1999, Pages 119-125

  Walubo, A ^a,b   Seger, D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

Author keywords

'Ecstasy'; Hyperthermia; MDMA; Multiorgan failure; Overdose

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ACUTE KIDNEY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; AUTOPSY; CASE REPORT; CLINICAL FEATURE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG BLOOD LEVEL; DRUG OVERDOSE; HUMAN; HYPERTHERMIA; INGESTION; MALE; MEDICAL LITERATURE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PRISONER; RHABDOMYOLYSIS; SUICIDE; SYMPATHETIC TONE; SYMPTOM; TIME;

DISSEMINATED INTRAVASCULAR COAGULATION; FATAL OUTCOME; FEVER; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RESPIRATORY DISTRESS SYNDROME, ADULT; RHABDOMYOLYSIS; SUICIDE;

EID: 0033060517     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/096032799678839707     Document Type: Article

References (91)

1. Merck E. Varfeharen zur darstellung von alkyloxyaryl-dialyoxyaryl-und alkylenodioxyaryl-aminopropanen bzw. deren am stickstoff monoalkylierten. German patent 1914; 274: 350.
2. Grinspoon L, Bakalar JB. Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 1986; XL: 393-404.
3. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 1986; 18: 335-340.
4. Greer G, Tolbert R. The therapeutic use of MDMA. In: Peroutka SJ (ed.) Ecstasy: The clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Kluwer, Boston, 1990.
5. Gaston TR, Rasmussen GT. Identification of 3,4-methylenedeoxymethamphetamine. Microgram 1980; 5: 251-254.
6. Ricaurte G et al. Hallucinogenic amphetamines selectively destroys brain serotonin nerve terminals. Science 1985; 229: 986-988.
7. Schimidt CJ, Wu L, Lovenberg W. Methylenedimethoxymethamphetamine; A potentially neurotoxic amphetamine analog. Eur J Pharmacol 1986; 124: 175-178.
8. Stone DM, Johnson M, Hanson GR, Gibb J. A comparison of the neurotoxic potential of methylenedeoxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur J Pharmacol 1987; 4: 245-248.
9. Commins DL et al. Biochemical and histological evidence that MDMA is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987; 241: 338-345.
10. Schmidt CJ. Neurotoxicity of psychedelic amphetamine. MDMA. J Pharmacol Exp Ther 1987; 240: 1-7.
11. Recaurte GA et al. 3,4-methylenedeoxymethphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988; 260: 51-55.
12. Battaglia G, Zackzek R, De Souza EB. MDMA effects in brain: pharmacologic profile and evidence of neurochemical and autoradiographic studies. In Peroutka SJ (ed.), MDMA: Ecstasy and/ or human neurotoxin. Kluwer, Norwell MA, 1989; pp 171-199.
13. Schimidt CJ, Kehne JH. Neutoxicity of MDMA: neurochemical effects. Ann NY Acad 1990; 600: 665-681.
14. Suarez RV, Reimersma R. 'Ecstasy' and sudden cardiac death. Am J Forensic Med Pathol 1985; 9: 339-341.
15. Siegel RK. MDMA, non-medical use and intoxication. J Psychoactive Drugs 1986; 18: 349-354.
16. Hayer GN, McKinney H. MDMA, the dark side of Ecstasy. J Psychoactive Drugs 1986; 18: 341-347.
17. Dowling GP, McDonough ET, Bast R. 'Eve' and 'ecstasy': a report of five deaths associated with the use of MDEA and MDMA. JAMA 1987; 257: 1615-1617.
18. Lawn JC. Schedules of controlled substances: temporary placement of 3,4-methylenedioxymeth-amphetamine (MDMA) into Schedule 1. Federal register 1985; 23: 23118-23120.
19. Greer G, Tolbort R. Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 1986; 18: 319-328.
20. Yount D. Teens flirt with the triple threat of 'designer drugs'. San Antonio Express News, April 5, 1987.
21. Poroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988; 1: 273-277.
22. Beck J et al. Exploring ecstasy: a description of MDMA users. Report to the National Institute on Drug Abuse (San Francisco, Institute of Science Analysis) 1989.
23. Peroutka SJ. Incidence of recreational use of 3,4-methylenedeoxymethamphetamine (MDMA, ecstasy) on undergraduate campus. N Eng J Med 1987; 317: 1542-1543.
24. Randall J. Ecstasy-fueled 'rave' parties become dances of death for English youths. JAMA 1992; 268: 1505-1506.
25. Randall T. Rave scene, ecstasy use, leap Atlantic. JAMA 1992; 268: 1506.
26. Seymor RB, Wesson DR, Smith DE. MDMA: A multidisciplinary forum on MDMA; proceedings of the conference. J Psychoactive Drugs 1968; 18: 287-373.
27. Jones C. Dickinson P. Substance abuse: from ecstasy to agony. Nursing Times 1992; 88: 28-30.
28. Gorard DA, Davies SE, Clark ML. Misuse of ecstasy. BMJ 1992; 305: 309.
29. Beck J. MDMA: The popularization and resultant implications of a recently controlled psychoactive substance. In: Contemporary drug Problems 1986; pp 23-61.
30. Henry JA. Ecstasy and the dance of death. BMJ 1992; 305: 5-6.
31. Solwij N, Hall W, Lee N. Recreational use of MDMA in Sydney: a profile of 'ecstasy' users and their experiences with the drug. Br J Addict 1992; 87: 1161-1172.
32. Fineschi V, Masti A. Fatal poisoning by MDMA (ecstasy) and MDEA: a case report. Intern J Legal Med 1996; 108: 272-275.
33. Schifano F, Magni G. MDMA ('ecstasy') abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiatry 1994; 36: 763-767.
34. Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 1992; 32: 91-95.
35. Wodarz N, Boning J. 'Ecstasy'-induced psychotic: depersonalization syndrome (see comments). (German) 'Ecstasy'-induziertes psychotisches Depersonalisationssyndrom. Nervenarzt 1993; 64: 478-480.
36. Skopp G, Aderjan R, Koster J. Hair analysis in the diagnosis of toxic hepatitis after Ecstasy abuse. [German] Haaranalyse zur Diagnose toxischer Hepatitiden nach Missbrauch von 'Ecstasy'. Deutsche Medizinische Wochenschrift 1995; 120: 1165-1168.
37. Hooft PJ, van de Voorde HP. Reckless behavior related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): apropos of a fatal accident during car-surfing. Intern J of Legal Med 1994; 106: 328-329.
38. Huarte Muniesa MP, Pueyo Royo AM. [Acute hepatitis due to ingestion of Ecstasy] [Spanish]) Hepatitis aguda tras consumo de extasis. Rev Espan Enferm Digest 1995; 87: 681-683.
39. Climko RP et al. Ecstasy; a review of MDMA and MDA. Int J Psychiatry Med 1986-87; 16: 359-372.
40. Barnes D. New data intensify the agony over ecstasy. Science 1998; 239: 864-866.
41. Grob C, Bravo G, Walsh R. Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Arch Gen Psychiatry 1990; 47: 288.
42. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoact Drugs 1986; 18: 335-340.
43. Nash JF, Meltzer HY, Gudelsky GA. Elevation of serum prolactin and corticosterone concentrations after administration of 3,4-methylenedeoxymethamphetamine. J Pharmacol Exp Ther 1988; 245: 873-879.
44. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedeoxymethamphotamine ('ecstasy'). Lancet 1992; 340: 286-288.
45. Satchell SC, Connaughton M. Inappropriate antidiuretic hormone secretion and extreme rises in serum creatinine kinase following MDMA ingestion. Br J Hasp Med 1994; 51: 495.
46. Holden R, Jackson MA. Near fatal hyponatremic come due to vasopressin over-secretion after 'ecstasy' (3,4-MDMA) (letter). Lancet 1996; 347: 1052.
47. Marsh JC et al. Aplastic anaemia following exposure to 3,4-methylenedioxymethamphetamine ('Ecstasy'). Br J Haematol 1994; 88: 281-285.
48. Cohen SR. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; 'ecstasy'). Biological Psychiatry 1996; 39: 819-820.
49. Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: An overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 1996; 19: 157-164.
50. Singarajah C, Lavies NG. An overdose of ecstasy; a role for dantrolene. Anaesthesia 1992; 47: 686-687.
51. Thomas SD. Malignant hyperthermia. Critical Care Nurse 1989; 9: 58-68.
52. Kline SS, Mauro LS, Scala-Barnett DM, Zick D. Serotonin syndrome versus nouroleptic malignant syndrome as a cause of death. Clin Pharm 1989; 8: 510-514.
53. Halman M, Goldbloom DS. Fluoxetine and neuroleptic malignant syndrome. Biol Psych 1990; 28: 518-521.
54. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705-713.
55. Ooi TK. The serotonin syndrome. Anaesthesia 1991; 46: 507-508.
56. Grahame-Smith DG. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with monoamine oxidase inhibitor and L-tryptophan. J Neurochem 1971; 18: 1053-1066.
57. Screaton GR et al. Hyperpyrexia and rhabdomyolysis after MDMA ('ecstasy') abuse. Lancet 1992; 339: 677-678.
58. Callaway CW, Rempel N, Peng RY, Geyer MA. Serotonin 5-HT1 like receptor mediate hyperactivity in rats induced by 3,4-methylenemethamphetamine. Neuropsychopharmacology 1992; 7: 113-127.
59. Gordon CJ, Wilkinson WP, O'Callaghan JP, Miller DB. Effect of 3,4-methylenedeoxymethamphotamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav 1991; 38: 339-344.
60. Schimidt CJ, Taylor VL. Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedeoxymethamphetamine. Biochem Pharmacol 1987; 36: 4095-4102.
61. Slikker Jr W et al. Behavioural and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicologv 1989; 10: 529-542.
62. Schimidt CJ, Black CK, Abbate GM, Taylor VL. Methylene dioxymethamphetamine induced hyperthermia and neurotoxicity are independently mediated by 5HT2 receptors. Brain Res 1990; 529: 85-90.
63. Johnson M et al. Effects of 3.4-methylenemethamphetamine and 2,4,5-trihydroxymethamphetmine, two metabolites of 3,4-methylenemethamphetamine, on central serotonergic and dopaminergic systems. J Pharmacol Exp Ther 1992; 261: 447-453.
64. Green AR, Cross AJ, Goodwill GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedeoxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology 1995; 119: 247-260.
65. Cooper KE, Craston WI, Honour AJ. Effects of intraventricular and intrahypothalamic injections of noradrenaline and 5-HT on body temperature in conscious rabbits. J Physiol 1965; 181: 852-864.
66. Bligh J. Temperature regulation in mammals and other vertebrates. North-Holland, Amsterdam, 1973.
67. Myers RD. Serotonin and thermoregulation: old and new views. J de Physiol 1981; 77: 505-513.
68. Lee TF, Mora F, Myers RD. Dopamine and thermoregulation: an evaluation with specific reference to dopaminergic pathways. Neurosc Biobehav Rev 1985; 9: 589-598.
69. Clark WG, Lipton JM. Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants II. Neurosc Biobehav Rev 1986: 10: 153-220.
70. Cooper KE (Ed.). The role of hypothalamic amines and putative neurotransmitters. In: Cooper KE (Ed). Fever and antipyresis, the role of the nervous system, Cambridge Univ Press, 1995; pp 22-150.
71. Willats SM, Winter RJ. Principles and protocols in intensive care. Ferrand Press, London, 1992, pp 341.
72. Fahal IH et al. Acute renal failure after ecstasy. BMJ 1992; 305: 29.
73. Gledhill JA, Moore DF, Bell D, Henry JA. Subarachnoid hemorrhage associated with MDMA abuse. Br J Pharmacol 1993; 84: 743-753.
74. Lim HK, Folz RL. Ion trap mass spectrometric evidence for the metabolism of 3,4,-(methyle-nedeoxy)methamphetamine (MDMA) to the potent neurotoxins 2,4,5,-trimethoxy and 2,4,5,-trihydroxyamphetamine. Chemi Res Toxicol 1991; 4: 626-632.
75. Chu T, Kumagai Y, DiStefano EW, Cho AK. Disposition of methylenedioxyamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 1996; 51: 789-796.
76. Kunsman GW et al. MDA-MDMA concentrations in urine specimens. J Anal Toxicol 1996; 20: 517-521.
77. Tucker GT et al. The demethylation of methylenedeoxymethamphetamine ('ecstasy') by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994; 47: 1151-1156.
78. Kumagai Y et al. Participation of cytochrome P450-2B and -2D isozymes in the demethylation of methylenedeoxymeth-amphethamine enantiomers by rats. Mol Pharmacol 1994; 45: 359-365.
79. Matsunuga E et al. The CY2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylation deficiency in DA rats. Biochemistry 1989; 28: 7349-7355.
80. Hardman H, Haavik C, Seevens M. Relationship of the structure of mescaline and seven analogues to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 1973; 25: 299-309.
81. Buchanan J, Brown C. 'Designer drugs' a problem in clinical toxicology. Med Toxicol 1988; 3: 1-17.
82. Brown C, Osterloh J. Multiple severe complications from recreational ingestion of MDMA ('ecstasy'). JAMA 1987; 258: 780-781.
83. Mckenna DJ, Peroutka SJ. Neurochemistry and neurotoxicity of 3,4-methylenedioxyamphetamine (MDMA, 'ecstasy'). J Neurochem 1990; 54: 14-22.
84. Richards CF, Clark RF, Holbrook T, Hoyt DB. The effect of cocaine and amphetamines on vital signs in trauma patients. J Emerg Med 1995; 13: 59-63.
85. Peroutka SJ, Newman H, Harris H. Subjective effects of 3.4,-methylenedeoxymethamphetamine in recreational users. Neuropsychopharmology 1988; 1: 273-278.
86. Bedford-Russell AR, Schwartz RH, Dawling S. Accidental ingestion of 'ecstasy' (3.4-methylenedeoxymethamphetamine). Arch Dis Child 1992; 67: 1114-1115.
87. Chadwick IS et al. Ecstasy, 3,4,-methylenedeoxymethamphetamine (MDMA), a fatality associated with coagulation and hyperthermia. J Royal Soc Med 1991; 84: 371.
88. McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA ('ecstasy'). BMJ 1991; 302: 697.
89. Campkin NT, Davies UM. Another death from Ecstasy. J Royal Soc Med 1992; 85: 61.
90. Nimmo SM et al. Drug-induced hyperthermia. Anaesthesia 1993; 48: 892-895.
91. Dar KJ, McBrien ME. MDMA induced hyperthermia: report of fatality and review of current therapy. Intensive Care Med 1996; 22: 995-996.